Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
| Autor: | Mark E. Robson, Chau T. Dang, Diana Lake, Katherine S. Panageas, Arti Hurria, Mary Ellen Moynahan, Maura N. Dickler, Clifford A. Hudis, Theresa Gilewski, Karen Lisa Smith, Steve Sugarman, Larry Norton, Tiffany A. Troso-Sandoval, Monica Fornier, Nancy Mills, Gabriella D'Andrea, Roshini George |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty Cyclophosphamide Paclitaxel medicine.medical_treatment Breast Neoplasms Pilot Projects Filgrastim Gastroenterology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Epirubicin Chemotherapy Taxane business.industry Middle Aged medicine.disease Docetaxel Female business Febrile neutropenia Pegfilgrastim medicine.drug |
| Zdroj: | Clinical breast cancer. 8(5) |
| ISSN: | 1526-8209 |
| Popis: | Purpose We conducted a pilot study of dose-dense epirubicin/cyclophosphamide (EC) × 6 → paclitaxel (P) × 6 with pegfilgrastim. A previous dose-dense trial of FEC (5-fluorouracil [5-FU]/EC) × 6 with filgrastim → by weekly paclitaxel alternating with docetaxel × 18 was not feasible because of pneumonitis (with dose-dense FEC) and pericardial/pleural effusion (taxane phase). Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility. Patients and Methods Patients with resectable breast cancer were enrolled, regardless of surgery status, tumor size, or nodal status. Treatment regimen consisted of every-2-week EC (100/600 mg/m 2 ) × 6 → by 2-weekly P (175 mg/m 2 ) × 6 with pegfilgrastim 6 mg on day 2. Results Between November 2004 and May 2005, 38 patients were enrolled. The median age was 47 years (range, 30-72 years); 33 of 38 (87%) were treated in the adjuvant setting and 27 of 33 (81%) had involved nodes (range, 1-46); 5 of 38 (13%) were treated pre-operatively; 33 of 38 (87%) completed all chemotherapy as planned; the remaining patients (13%) had treatment modifications for toxicity. Febrile neutropenia occurred in 6 of 38 patients (16 %) and only during EC. There were 12 hospitalizations in 9 of 38 patients (24%) enrolled. Conclusion Dose-dense every-2-week EC × 6 → P × 6 with pegfilgrastim is feasible based on our prospective definition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect